Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.5K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.5K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.6K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Cancer Vaccines01:30

Cancer Vaccines

1.3K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.3K
Cancer Therapies02:49

Cancer Therapies

8.2K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.2K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Analysis of a cancer-care based diagnosis program for lymphoma.

Leukemia & lymphoma·2025
Same author

De-escalated Induction Therapy and Thiotepa/Busulfan-based Autologous Stem Cell Transplantation for Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2024
Same author

Long-term immune changes in patients with relapsed/refractory chronic lymphocytic leukemia following treatment with venetoclax plus rituximab.

HemaSphere·2024
Same author

Canadian cancer trials group LY.17: A randomized phase II study evaluating novel salvage therapy pre-autologous stem cell transplant in relapsed/refractory diffuse large B-cell lymphoma-outcome of rituximab-dose-intensive cyclophosphamide, etoposide, cisplatin (R-DICEP) versus R-GDP.

British journal of haematology·2024
Same author

Overview of the Engagement Process to Develop the Future of Cancer Impact (FOCI) Report in Alberta: The Power of Collective Action.

Current oncology (Toronto, Ont.)·2024
Same author

High-dose chemotherapy with autologous stem-cell transplantation for relapsed metastatic germ cell tumors The Alberta experience.

Canadian Urological Association journal = Journal de l'Association des urologues du Canada·2023

Related Experiment Video

Updated: Apr 29, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K

Obinutuzumab for B-cell malignancies.

Carolyn J Owen1, Douglas A Stewart

  • 1University of Calgary, Tom Baker Cancer Centre, Division of Hematology and Hematological Malignancies , 603 South Tower, Foothills Medical Centre, 1403-29th St NW, Calgary, Alberta, T2N 2T9 , Canada carolyn.owen@albertahealthservices.ca.

Expert Opinion on Biological Therapy
|May 27, 2014
PubMed
Summary

Obinutuzumab shows superiority over rituximab in treating chronic lymphocytic leukemia (CLL). This advanced anti-CD20 antibody offers improved outcomes for CD20(+) malignancies, including CLL and non-Hodgkin lymphoma (NHL).

Keywords:
CD20antibodychronic lymphocytic leukaemianon-Hodgkin lymphoma

More Related Videos

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.2K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.4K

Related Experiment Videos

Last Updated: Apr 29, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

11.8K
Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies
09:54

Assessment of Human Natural Killer Cell Events Driven by FcγRIIIa Engagement in the Presence of Therapeutic Antibodies

Published on: May 22, 2020

4.2K
A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

14.4K

Area of Science:

  • Hematology
  • Oncology
  • Immunotherapy

Background:

  • CD20-targeted monoclonal antibodies (mAbs) like rituximab have improved survival in B-cell malignancies.
  • Many patients with CD20(+) malignancies, including chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), relapse or become refractory to rituximab therapy.
  • Development of novel anti-CD20 mAbs is crucial for overcoming treatment resistance.

Purpose of the Study:

  • To analyze the efficacy of obinutuzumab in treating CD20(+) lymphoproliferative disorders, with a specific focus on chronic lymphocytic leukemia (CLL).
  • To provide an overview of obinutuzumab, including its mechanisms of action and clinical trial results.
  • To compare the effectiveness of obinutuzumab with rituximab in CD20(+) malignancies.

Main Methods:

  • Review of data from Phase I-III clinical studies of obinutuzumab.
  • Analysis of obinutuzumab's mechanism of action as a humanized anti-CD20 mAb.
  • Comparison of obinutuzumab with rituximab, particularly in the context of the CLL11 Phase III study.

Main Results:

  • Obinutuzumab demonstrated superiority over rituximab in the CLL11 Phase III study.
  • Obinutuzumab has shown safety and efficacy in Phase I/II studies for CD20(+) NHL.
  • Results from ongoing Phase III studies in NHL are anticipated.

Conclusions:

  • The superiority of obinutuzumab over rituximab in CLL presents a potentially practice-changing advancement.
  • Obinutuzumab is a safe and effective option for CD20(+) NHL, with further Phase III data pending.
  • The introduction of obinutuzumab holds immense potential for improving patient outcomes in CLL and NHL.